Vicore Pharma Holding AB (publ) Market Cap ($279.94 Million)
Market Cap & Net Worth: Vicore Pharma Holding AB (publ) (VICO)
Vicore Pharma Holding AB (publ) market cap. Vicore Pharma Holding AB (publ) (ST:VICO) has a market capitalization of $279.94 Million (Skr2.60 Billion) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #14856 globally and #244 in its home market, demonstrating a -0.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vicore Pharma Holding AB (publ)'s stock price Skr9.24 by its total outstanding shares 281525593 (281.53 Million). Also see VICO cash flow conversion for how efficiently the company converts equity into cash flow.
Vicore Pharma Holding AB (publ) Market Cap History (2015–2026)
Vicore Pharma Holding AB (publ) market cap history from 2015 to 2026. Data shows growth from $163.15 Million to $279.94 Million (5.41% CAGR). Check latest Vicore Pharma Holding AB (publ) stock price today for real-time trading data and today's change.
Vicore Pharma Holding AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vicore Pharma Holding AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Vicore Pharma Holding AB (publ) to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
89.69x
Vicore Pharma Holding AB (publ)'s market cap is 89.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $488.33 Million | $852.00K | -$6.65 Million | 573.15x | N/A |
| 2017 | $421.74 Million | $932.00K | -$12.86 Million | 452.51x | N/A |
| 2018 | $484.75 Million | $508.00K | -$21.68 Million | 954.23x | N/A |
| 2024 | $256.01 Million | $109.35 Million | -$168.63 Million | 2.34x | N/A |
| 2025 | $342.35 Million | $3.82 Million | -$477.47 Million | 89.69x | N/A |
Competitor Companies of VICO by Market Capitalization
Companies near Vicore Pharma Holding AB (publ) in the global market cap rankings as of November 4, 2026. Also see balance sheet size of Vicore Pharma Holding AB (publ) for a full breakdown of the balance sheet.
Key companies related to Vicore Pharma Holding AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Vicore Pharma Holding AB (publ) (2015–2026)
Market capitalization of Vicore Pharma Holding AB (publ) from 2015 to today. Between 2015 and today, Vicore Pharma Holding AB (publ)'s market cap moved from $163.15 Million to $ 279.94 Million, with a yearly change of 5.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr279.94 Million | -18.23% |
| 2025 | Skr342.35 Million | +33.73% |
| 2024 | Skr256.01 Million | -40.41% |
| 2023 | Skr429.61 Million | -20.78% |
| 2022 | Skr542.31 Million | +28.59% |
| 2021 | Skr421.73 Million | -55.81% |
| 2020 | Skr954.34 Million | +114.29% |
| 2019 | Skr445.36 Million | -8.12% |
| 2018 | Skr484.75 Million | +14.94% |
| 2017 | Skr421.74 Million | -13.64% |
| 2016 | Skr488.33 Million | +199.32% |
| 2015 | Skr163.15 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Vicore Pharma Holding AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $279.94 Million USD |
| MoneyControl | $279.94 Million USD |
| MarketWatch | $279.94 Million USD |
| marketcap.company | $279.94 Million USD |
| Reuters | $279.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial f… Read more